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Abstract
Background: The oral multi-kinase inhibitor sunitinib malate improves the survival of patients with gastrointestinal
stromal tumors (GIST) after the disease progresses or intolerance to imatinib mesylate develops. Urinary fistulae
arising during treatment with sunitinib for GIST have not been described.
Case presentation: We describe a 62-year-old female patient diagnosed with unresectable GIST that involved the
abdominal wall, urinary bladder wall, bowel, mesentery and peritoneum in the pelvic cavity. Intestinocutaneous
fistulae developed on a surgical lesion after orally administered imatinib was supplemented by an arterial infusion
of 5-flurouracil. Sunitinib was started after the patient developed resistance to imatinib. On day 4 of the fourth
course of sunitinib, a widely dilated cutaneous fistula discharged large amounts of fluid accompanied by severe
abdominal pain. Urinary communication was indicated based on the results of an intravenous injection of indigo
carmine. Computed tomography findings suggested a small opening on the anterior urinary bladder wall and
fistulous communication between the bladder and abdominal walls bridged by a subcutaneous cavity. The fistula
closed and the amount of discharge decreased when sunitinib was discontinued. Therefore, sunitinib might have
been associated with the development of the vesicocutaneous fistula in our patient.
Conclusion: This is the first description of a vesicocutaneous fistula forming while under sunitinib treatment.
Clinicians should be aware of the possible complication of vesicocutaneous fistula formation during treatment with
molecular targeting agents in patients with extravesical invasion and peritoneal dissemination of GIST.
Background
Sunitinib malate is a multi-kinase inhibitor of platelet-
derived growth factor receptors (PDGFRa,P D G R F b),
vascular endothelial growth factor receptors (VEGFR1,
VEGFR2, VEGFR3), stem cell factor receptor (KIT), Fms-
like tyrosine kinase-3 (FLT3), colony-stimulating factor
receptor Type 1 (CSR-1R), and the neurotrophic factor
receptor (RET) derivative of a glial cell line [1]. Sunitinib
has improved clinical outcomes for patients with progres-
sive unresectable gastrointestinal stromal tumors (GIST)
or who develop intolerance to imatinib mesylate and it is
reasonably well tolerated [1-5]. A Phase III GIST study
found objective response rates in sunitinib and placebo
groups of 7% and 0%, respectively (p = 0.006) [6]. Only
9% of patients discontinued sunitinib therapy due to
adverse events compared with 8% in the control group.
The most common adverse reactions that occurred in
over 20% of patients were fatig u e( 3 4 % ) ,d i a r r h e a( 2 9 % ) ,
skin discoloration (25%), nausea (24%) and anorexia
(19%), and all were typically of mild to moderate
intensity.
An adjacent organ is usually displaced by GIST. Fis-
tula formation is rare in patients with untreated GIST
and in those treated with sunitinib for intra-abdominal
malignancies [7]. We describe the clinical aspects of a
rare vesicocutaneous fistula that was associated with
sunitinib therapy.
Case presentation
A 62-year-old woman was diagnosed with c-kit-positive
GIST of the ascending colon with a single hepatic
lesion. She was surgically treated by right hemicolect-
omy and partial hepatectomy. A histological assessment
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metastasis. Therefore, imatinib mesylate (400 mg/day)
was started. After 2 years of imatinib treatment, the dis-
ease recurred in the liver, mesentery and peritoneum.
Increasing the dose of imatinib to 600 mg/day did not
prevent disease progression, so an arterial infusion of 5-
fluorouracil (5-FU) was added to the imatinib treatment
for 3 months. Thereafter, intestinocutaneous fistulae
developed on the previous surgical wound and she was
referred to our hospital for further treatment for
recurrence.
Her baseline performance status was excellent. A phy-
sical examination revealed right-sided abdominal tender-
ness. A small amount of a fetid discharge exuded from
the cutaneous fistulae, suggesting communication with
the intestine. An ostomy bag was therefore placed
around the fistulae. Contrast-enhanced computed tomo-
graphy (CT) images revealed that an abdominal mass
involved the abdominal wall, urinary bladder wall,
bowel, mesentery and peritoneum in the pelvic cavity
(Figure 1A and 1E) and that a 1.3-cm low-density lesion
was located in the right lobe of the liver. Signs of active
infection had been absent.
Sunitinib was initiated as a standard regimen (50 mg/
day for 4 weeks, every 6 weeks) for the peritoneal and
liver metastases. The patient developed mild diarrhea
(NCI Common Terminology Criteria for Adverse
Events; grade 2) accompanied by mild abdominal pain,
fever and leukocytosis on day 11 of the first course of
sunitinib. No obvious signs of infection sign were evi-
dent on CT images or in culture samples of urine, stool,
blood and sputum. Sunitinib was re-administered at a
dose of 37.5 mg/day. The patient developed grade 2
hypothyroidism on day 8 and grade 3 vomiting with
severe dehydration on the day 18 of the second course.
Therefore, sunitinib was discontinued until recovery.
Figure 1 CT findings. U, urinary bladder; T, tumor (GIST); C, subcutaneous cavity. Tumor was located between abdominal wall (A) and urinary
bladder (E) before sunitinib therapy. Abdominal tumor was smaller on day 4 of fourth course of sunitinib (B and F). Vesicocutaneous fistula
bridged by subcutaneous cavity at onset of abdominal pain (C and G). Small opening (arrow) at anterior bladder wall. Air collected in urinary
bladder. Fistula healed after sunitinib discontinuation (D and H) and subcutaneous cavity became smaller.
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ated a reduced dose of 25 mg/day, despite the presence
of grade 1 non-hematological toxicities such as hand-
foot syndrome, nausea and diarrhea. At the end of the
third course, she had frequent urination with micro-
hematuria. Leukocytopenia and elevated C-reactive pro-
tein were not found. The symptoms disappeared during
antibiotic therapy.
O nd a y4o ft h ef o u r t hc o u r s eo fs u n i t i n i b ,t h ea b d o m -
inal mass was reduced on CT images (Figure 1B and 1F)
and the hepatic mass decreased in density but not in size.
Immediately after this CT examination, the patient devel-
oped severe abdominal pain with moderate muscle
defense. A large amount of fluid material was concomi-
tantly discharged from the cutaneous fistulae. Urinary
communication was indicated from the results of an
intravenous indigo carmine injection. The fistula orifice
was markedly dilated on CT images (Figure 1C and Fig-
ure 2A) and a small opening in the anterior bladder wall
was evident (Figure 1G). Urinary leakage was localized in
the subcutaneous cavity and pan-peritonitis was not evi-
dent. The abdominal symptoms gradually improved with
decreased fluid drainage after sunitinib was discontinued.
One month later, the size of the fistula had also obviously
decreased (Figure 1D and 1H) and the fistula orifice was
closed (Figure 2B). The clinical course indicated that
sunitinib might have been associated with formation of
the vesicocutaneous fistula in our patient.
Discussion
Sunitinib is reasonably well tolerated and patients with
GIST seldom develop fistulae while under treatment with
this drug [3,6]. The GIST in our patient involved a cuta-
neous fistula on a previous surgical wound and another on
the urinary bladder wall. Vesicocutaneous fistulae developed
while she was under treatment with sunitinib, and healed
upon discontinuing the drug. These findings indicated that
sunitinib might be associated with the fistula formation.
Sunitinib reduced the tumor at the onset of vesicocu-
taneous fistula formation (Figure 1B and 1F). A multi-
centre phase II study (NCIC CTG Trial IND.184)
evaluated the activity of sunitinib in 19 women with
locally advanced or metastatic cervical carcinoma [8].
The patients enrolled in that study, including four who
developed fistulae, did not achieve objective responses.
On the other hand, notable tumor shrinkage resulted in
the complete healing of a fistula in a patient with GIST
under imatinib therapy [9]. Taken together, tumor
reduction alone might not be sufficient for fistula forma-
tion and other mechanisms are suggested.
Sunitinib has potent anti-angiogenic effects and it
exerts anti-tumor activities by inhibiting blood vessel
growth via inhibition of the VEGF-VEGFR pathway
[5,6]. These anti-angiogenic properties play a critical
role in impaired mucosal homeostasis and wound heal-
ing. Sunitinib causes tumors to shrink and tumor cell
necrosis results as a consequence of a decrease in the
number of vessels and reduced blood flow in the center
of tumors [6,10]. Urinary leakage in our patient was
localized to the cavity that formed between a potentially
fragile urinary bladder wall and the part of the abdom-
inal wall that involved GIST. Rapid degradation in the
center of a tumor contrasting with a sustained rim of
well-vascularized tumor tissue in the surrounding area
can form a pseudo-capsule at the interface between a
tumor and normal tissue [6].
Conclusions
This is the first description of a vesicocutaneous fistula
forming while under sunitinib treatment in a patient
Figure 2 Gross findings on day 4 of fourth course of sunitinib (A) and after its discontinuation (B). Cutaneous fistula orifice closed after
sunitinib discontinuation.
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Page 3 of 4with GIST. The anti-tumor effect of the drug might be
associated in part with the development of vesicocuta-
neous fistulae. The tumor involved the abdominal wall,
urinary bladder wall, bowel, mesentery and peritoneum
in the pelvic cavity. Clinicians should be aware of the
possibility of vesicocutaneous fistula formation in
patients with peritoneal metastasis of GIST during treat-
ment with molecular targeting agents.
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